Shares of biopharmacuetical company Immunron (NASDAQ: IMRN) shot up over 100% in the premarket following the release of their fourth quarter results.
- Immunron shares were higher on elevated volume after they posted a 52% jump in North American sales that hit $1.16 million.
- Travelan sales were up 32% and sales in Canada were up over $100k for Q4.
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company’s lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty-liver diseases.